Quick Takeaways
- Affinity Asset Advisors, LLC filed SCHEDULE 13G/A for Inozyme Pharma, Inc. Common Stock, par value $0.0001 per share (INZY).
- Disclosed ownership: 2.9%.
- Date of event: 20 May 2025.
Affinity Asset Advisors, LLC - 20 May 2025 SCHEDULE 13G/A Report for Inozyme Pharma, Inc. Common Stock, par value $0.0001 per share (INZY)
- Filing Manager
- Affinity Asset Advisors, LLC
- Reporting Manager
- Affinity Healthcare Fund, LP
- Symbol
- INZY
- Shares outstanding
- 64,626,644 shares
- Disclosed Ownership
- 1,867,710 shares
- Ownership
- 2.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 30 May 2025, 17:24:02 UTC
- Date of event
- 20 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Affinity Asset Advisors, LLC disclosed 2.9% ownership in Inozyme Pharma, Inc. Common Stock, par value $0.0001 per share (INZY) on 20 May 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 30 May 2025, 17:24.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Affinity Healthcare Fund, LP | 2.9% | 1,867,710 | 0 | 1,867,710 | /s/ Andrew Weinstein | Andrew Weinstein | |
| Affinity Asset Advisors, LLC | 2.9% | 1,867,710 | 0 | 1,867,710 | /s/ Andrew Weinstein | Andrew Weinstein |